Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2019-003218-15-PL
EUCTR2019-003218-15-PL
Active, not recruiting
Phase 1

A phase IV interventional study to assess the disease-modifying effect of long-term treatment with tildrakizumab in adult patients with moderate-to-severe plaque psoriasis - MODIFY

Almirall S.A.0 sites47 target enrollmentSeptember 6, 2019
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsModerate to severe plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
DrugsIllumetri

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Moderate to severe plaque psoriasis
Sponsor
Almirall S.A.
Enrollment
47
Status
Active, not recruiting
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 6, 2019
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Provide written informed consent prior to perform any study\-related activity
  • •2\. Has completed the long\-term extension of the reSURFACE 2 study
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 40
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 7

Exclusion Criteria

  • •1\. Patients unable to comply with the requirements of the study
  • •2\. Patients who in the opinion of the investigator should not participate in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
Outpatient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients > 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant studyRelapsed or refractory CD20 positive diffuse large B-cell lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
ACTRN12606000373572Roche40
Active, not recruiting
Phase 1
Study comparing Treatment with Alluzience vs Reconstituted toxin (STAR)Moderate to severe glabellar lines (GL).MedDRA version: 21.1Level: LLTClassification code 10052609Term: Glabellar frown linesSystem Organ Class: 100000004858Therapeutic area: Not possible to specify
EUCTR2021-004748-62-DEQ-Med AB, part of the Galderma Group150
Recruiting
Phase 4
A prospective, phase IV study to check the effectiveness and safety of everolimus in liver transplant in Indian patientsHealth Condition 1: null- Liver Transplant
CTRI/2018/07/014916ovartis India Limited
Recruiting
Phase 4
A clinical trial to evaluate aflibercept treatment in patients with diabetic macular edema.Health Condition 1: H353- Degeneration of macula and posterior pole
CTRI/2022/08/044792Bayer Zydus Pharma Private Limited
Active, not recruiting
Phase 4
To compare combination of study with marketed other combination of drug in patients having both anxiety and depression.Health Condition 1: F418- Other specified anxiety disorders
CTRI/2022/11/047050Mankind Pharma Limited